Johnson & JohnsonvsMedline

JNJ and MDLN stock compared: price, dividend, valuation and results, from SEC filings.

MDLN

Medline Inc.

$39.16

Value $31.7B

+3.93%
MDLN's page

Johnson & Johnson (JNJ) has a market value of $657B and Medline (MDLN) $31.7B. The P/E is 40.8 for JNJ and 54.5 for MDLN. Dividend yield: JNJ 1.94%, MDLN none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    JNJ$657B

    MDLN$31.7B

    JNJ is 21 times MDLN

  • Revenue, 12 months

    JNJ$99.3B

    MDLN$30.7B

    JNJ is 3.2 times MDLN

  • Net income, 12 months

    JNJ$16.1B

    MDLN$582M

    JNJ is 28 times MDLN

  • Operating margin

    JNJ–

    MDLN5.7%

  • ROIC

    JNJ12.4%

    MDLN5.7%

    6.7 points apart

  • P/E

    JNJ40.8

    MDLN54.5

    MDLN is 1.3 times JNJ

  • Dividend yield

    JNJ1.9%

    MDLN0.0%

    1.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

JNJ+31.7%

MDLN-4.5%

801001202026

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

JNJJohnson & JohnsonMDLNMedline

Valuation

JNJMDLN
Valuation
Price$272.70$39.16
Market value$657B$31.7B
Enterprise value (EV)$685B$40.7B
P/E40.854.5
P/E, 5-year median21.9–
P/B8.12.7
EV/EBIT38.623.4
Free cash flow yield3.1%6.0%

Results and growth

JNJMDLN
Results and growth
Revenue, 12 months$99.3B$30.7B
Net income, 12 months$16.1B$582M
Free cash flow, 12 months$20.6B$1.9B
Earnings per share, 12 months$6.59$0.72
Revenue growth, year on year6.1%11.5%
Revenue growth a year, past+2.7%over 5 years+10.6%over 2 years
EPS growth a year, past+14.9%over 5 years–

Margins and returns on capital

JNJMDLN
Margins and returns on capital
Gross margin67.6%25.7%
Operating margin–5.7%
Net margin16.2%1.9%
ROIC12.4%5.7%
ROE19.7%5.4%

Balance sheet

JNJMDLN
Balance sheet
Cash$17.2B$3.6B
Total debt$44.7B$12.6B
Net debt / EBITDA1.13.3
Interest cover18.0×2.5×

Dividends and buybacks

JNJMDLN
Dividends and buybacks
Dividend yield1.9%–
Dividend per share, 12 months$5.28–
Dividend growth a year, past+5.3%over 5 years–
Buyback yield0.9%0.1%
Shareholder yield2.9%0.1%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: JNJ or MDLN

Didn't find what you were looking for?

Ask us
Which is bigger, Johnson & Johnson or Medline?

By market value, Johnson & Johnson ($657B) is about 20.7 times Medline ($31.7B), at today's prices.

Which pays the higher dividend, JNJ or MDLN?

The dividend yield at today's price is 1.94% for Johnson & Johnson and none for Medline. Over the last twelve months they paid $5.28 and – per share.

What is the P/E of JNJ and MDLN?

At today's price, the P/E is 40.8 for JNJ and 54.5 for MDLN. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Johnson & Johnson or Medline?

Over the last twelve months, the net margin was 16.2% for Johnson & Johnson and 1.9% for Medline, and the operating margin – and 5.7%. Revenue was $99.3B and $30.7B.

Which is the better investment, Johnson & Johnson or Medline?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.